Mass spectrometry analyses revealed that the unusual structures include sulfated oligosaccharides. The structures of the glycosphingolipids of the cancer cells from these two cases were analyzed by methods which include enzymatic release of carbohydrate moieties, fluorescent labeling with aminopyridine and identification using two-dimensional mapping, enzymatic digestion and mass spectrometry together with methanolysis, and the use of newly synthesized sulfo-fucosylated oligosaccharides as standards. The colon cancer cells from one of the patients demonstrate a variety of oligosaccharides as major components which are sulfated at the C6 position of subterminal GlcNAc and at C3 positions of terminal galactose with or without sialylation or fucosylation. These include 6-sulfo Le x , 6 -sialyl 6-sulfo lactosamine, and 3 -sialyl 6-sulfo Le x , in addition to sialylated or fucosylated derivatives of type-1 and type-2 hybrid oligosaccharides. The colon cancer cells from the other patient have two kinds of sulfated oligosaccharides, a 6-sulfo Le x structure and a 3 -sulfo Le x structure, as minor components. Taking into consideration the clinical features of the two patients, the biological significance of sulfated glycosphingolipids on cancer cells is discussed.
Introduction
Malignant transformation is frequently accompanied by a drastic alteration in the structures of oligosaccharides of the cell surface (Hakomori 1989 (Hakomori , 2002 . Subsequent series of studies have indicated the functional significance of aberrant glycosylation in cancer malignancy, such as metastasis and invasion (Hakomori 1996 (Hakomori , 2002 Ono and Hakomori 2004) . In our recent study, in order to pursue the association between aberrant glycosylation and cancer malignancy, we comprehensively and precisely analyzed the structures of glycosphingolipids (GSLs) from highly purified colorectal cancer cells (CCs) and normal colorectal epithelial cells (NCs) of 16 patients (Misonou et al. 2009 ). We reported the alteration in the structures of GSLs in carcinogenesis in general and that characteristic patterns tend to be associated with clinical features such as hepatic metastasis (Misonou et al. 2009 ). In brief, GSLs of human NCs are mostly composed of neutral GSLs, such as LacCer and Le a . Three specific alterations were observed in malignant transformation, namely increased ratios of type-2 oligosaccharides, increased α2-3 and/or α2-6 sialylation, and increased α1-2 fucosylation. These alterations result in increases in the amount of or appearance of Le x , LST-c, Le y , Le b , sialyl Le x , sialyl Le a , IV 6 NeuAcαIV 2 Fucα-nLc 4 , V 3 FucαIII 3 Fucα-nLc 6 , VI 3 NeuAcα-nLc 6 , and VI 6 NeuAcαIII 3 Fucα-nLc 6 . Furthermore, a shift from type-1 dominant NCs to type-2 dominant CCs was found in the five cases having hepatic metastasis. We have subsequently analyzed the structures of GSLs from CCs and NCs to increase the number of analyzed cases in order to confirm the findings previously reported and to further investigate other characteristic alterations associated with other clinical features such as lung metastasis, invasion to adjacent tissues, and low metastatic potential. While similar results to those previously reported were obtained in most cases, we found that the CCs from two cases accumulated unusual GSLs, which were not found in CCs and NCs of the other cases. Taking into consideration the clinical features, such as tumor size, depth of invasion, metastasis to lymph node, and long distance organs, both cases are estimated to have low metastatic potential. Tandem mass spectrometry analyses of these unusual oligosaccharides revealed that CCs from both patients include sulfated GSLs, most of which were sialylated and/or fucosylated, and one set of CCs include isomers of GSLs normally observed in CCs.
Human tissues contain varieties of sulfoglycolipids, such as SM4s, SM4g, SM3, SMGb4, SMGb5, SMUnLc 4 , and SMUnLc 6 , and the presence of SM3 and SM4 in colon cancer tissues has been reported from our and other laboratories (Fukushi et al. 1984; Ishizuka 1997 ; Korekane et al. 2007 ). However, the structures of the unusual sulfoglycolipids found in the CCs in these two cases have not been reported to date. Carbohydrate sulfation occurs in a number of biological compounds, such as proteoglycans, glycoproteins, and GSLs, and the biological significance of sulfation of carbohydrates has been demonstrated in a variety of systems including the reproductive system, immune system, and embryonic development (Bullock et al. 1998; Forsberg et al. 1999; Humphries et al. 1999; Tangemann et al. 1999; Hemmerich et al. 2001; Honke et al. 2002) . However, the involvement of the accumulation of sulfated carbohydrates in cancer malignancy has not been well studied.
Sulfated glycosphingolipids in colon cancer cells
In this study, we elucidate the fine structures of the major GSLs of CCs and NCs from the two patients which include a variety of sulfated GSLs. The significance of the sulfated GSLs is considered in Discussion.
Results

Preparation of PA-oligosaccharides from CD326-positive colon adenocarcinoma cells and normal colon epithelial cells from two colon cancer patients
The clinicopathological features of the two patients are described in Table I . The colon cancer in case 1 is thought to have very low metastatic potential because it was very large (100 × 120 mm), invaded the bladder but did not metastasize to lymph nodes and long-distance organs such as liver and lung (Table I) . More than 2 years have passed since removal of the primary colon cancer and bladder by operation, but there has been no recurrence in this case. The colon cancer in case 2 is also thought to have low metastatic potential. The size of the primary cancer was 80 mm × 41 mm and invaded the subserosa, but no lymph node or long-distance metastasis were detected, as in case 1 (Table I) . No recurrence was found in this case either. PA-oligosaccharides of GSLs were prepared from CCs and NCs from the two cases (cases 1 and 2), which were isolated with high purity from the colon cancer tissues and surrounding normal colon epithelial tissues using magnetic beads labeled with antibody against the epithelial cell marker, CD326.
Structural analysis of PA-oligosaccharides of case 1
The neutral and acidic PA-oligosaccharides from purified CCs and NCs from case 1 were analyzed by size-fractionation highperformance liquid chromatography (HPLC) (Figure 1 ). Fifteen (N1-N15) and 23 peaks (A1-A23) were obtained from neutral and acidic GSLs of the CCs, respectively ( Figure 1C and A) , and two peaks (N1 and N7-1) and three peaks (A1, A2, and A9) from neutral and acidic GSLs of NCs ( Figure 1D and B) . The profiles of both acidic and neutral GSLs from NCs from this patient are similar to those from the colon cancer patients as reported in our recent paper ( Figure 1B and D) . Thus, the neutral GSLs are mainly composed of lactose and Le a (N1 and N7-1 in Figure 1D ) and acidic GSLs composed of SM3, GM3 with LSTc as a very minor component (A1, A2, and A9 in Figure 1B ). In contrast, the profile of GSLs, especially the acidic fraction, from CCs from this patient shows a variety of peaks in addition to the common characteristic peaks of CCs. Peaks in the neutral and acidic GSLs, A1, A2, A4, A9, A11, A12, A16, A22, A23, N1, N2, N3, N5, N7, N9, N10, N11, N15 (closed arrows), are observed in CCs from many cases. However, the other peaks (open arrow) have rarely been observed in human CCs. The structures of all the major peaks observed from the CCs were analyzed by a combination of a 2D mapping technique, enzymatic digestion, methanolysis, and mass spectrometry analyses as described below.
Each of the peaks was further purified by reversed-phase HPLC. Peaks N7, N10, N12, N13, A10, A13, and A16 were separated into two major components in reversed-phase HPLC, and each designated N7-1, N7-2, N10-1, N10-2, N12-1, N12-2, N13-1, N13-2, A10-1, A10-2, A13-1, A13-2, A16-1, and A16-2. Additionally, purified PA-oligosaccharides were subjected to LC/ESI MS/MS. Elution positions of N1-N15 and A1-A23 on size fractionation and reversed-phase HPLC are summarized in Figure 2 as a 2D map.
From comparison of the positions on the map to the positions of standard PA-oligosaccharides, N1, N2, N3, N4, N5, N6, N7-1, N7-2, N8, N9, N10-1, N11, N12-1, N14, N15, A1, A2, A3, A4, A7, A8, A9, A11, A12, A16-1, A22, and A23 are predicted to be lactose, Lc 3 , Globo-N-tetraose (Gb 4 ), lacto-N-tetraose (Lc 4 ), lacto-N-neotetraose (nLc 4 ), lacto-N-fucopentaose I ( Figure 2 ). The structures of these 2D matched oligosaccharides were also confirmed by mass spectrometry. Fractions N10-2, N12-2, N13-1, N13-2, A5, A6, A10-1, A10-2, A13-1, A13-2, A14, A15, A16-2, A17, A18, A19, A20, and A21 do not match any of the reference compounds on the 2D map accumulated prior to our studies. Elution positions, mass data, and estimated composition of these unmatched oligosaccharides are presented in Table III . In the following results sections, the structures of these PAoligosaccharides are explained in detail.
Structure of N10-2, N12-2, and N13-2 MS 2 analysis revealed that N10-2 has a lacto or neolacto series hexasaccharide structure, Hex-HexNAc-Hex-HexNAcHex-Hex-PA, but the position of N10-2 on the 2D map does not match to nLc 6 . N10-2 was digested with lacto-N-biosidase, and the products of the digestion ran as two peaks by HPLC, corresponding to Galβ1-4Glc-PA and K Shida et al. Galβ1-4GlcNAcβ1-3Galβ1-4Glc-PA Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc-PA Galβ1-3GlcNAcβ1-3Galβ1-4Glc-PA on the map, indicating the structure of the backbone to be Galβ1-3GlcNAc-Galβ1-3GlcNAcβ1-3Galβ1-4Glc-PA. Hydrolysis of N10-2 with endo-β-galactosidase gave two peaks by HPLC, corresponding to Glc-PA and GlcNAcβ1-3Galβ1-4Glc-PA. These results indicate that the subterminal GlcNAc is linked β1-3 to galactose. Hence, the structure of N10-2 is predicted to be Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc (Lc 6 ). The structures of N12-2 and N13-2 were estimated to be VI 2 Fucα-Lc 6 and VI 3 GalNAcαVI 2 Fucα-Lc 6 , respectively, since the digestion product of N12-2 with α1,2-fucosidase and sequential digestion product of N13-2 with α-N-acetylgalactosaminidase, and then α1,2-fucosidase gave products which ran at the same position as Lc 6 , as was determined in the above experiment.
Structure of N13-1 and A18
After sequential digestion with α1,3/4-fucosidase, β1,4-galactosidase, and β-N-acetylhexosaminidase, the digestion products of N13-1 ran on the 2D map at the same position as reference compound Lc 4 . Under the conditions used in this study, α1,3/4-fucosidase can cleave a fucosyl residue linked to a subterminal fifth GlcNAc, but not an internal third GlcNAc. From these results and enzyme specificity, the structure of N13-1 is tentatively predicted to be Galβ1-4(Fucα1-3)HexNAc-Galβ1-3GlcNAcβ1-3Galβ1-4Glc. After the fucosyl residue of N13-1 was digested with α1,3/4-fucosidase, the defucosylated product was cleaved by endo-β-galactosidase. The products of the digestion showed two peaks by HPLC, corresponding Glc-PA and GlcNAcβ1-3Galβ1-4Glc-PA, indicating that the subterminal HexNAc is GlcNAc linked β1-3 to galactose. Hence, the structure of N13-1 is predicted to be Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc (V 3 Fucα-1,2 Lc 6 ). Sialylated GSL A18 was digested with α2,3-sialidase in conditions in which this enzyme cleaves the terminal α2,6-linkage (see Material and methods). The digestion product ran on the 2D map at the same position as the defucosylated product of N13-1. The structure of A18 is thus predicted to be NeuAcα2-6Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc (VI 6 NeuAcα-1,2 Lc 6 ).
Structure of monosulfated GSLs, A5, A6, A10-1, A13-2, A14, A15, A16-2, A17, A19, A20, and A21 A5, A6, A10-1 A14, A15, and A20 are nonsialylated but have a HSO 3 -6GlcNAc structure at their subterminal or terminal GlcNAc, as evidenced below. Our preliminary experiments revealed that methanolysis under the conditions used in this study hydrolyzes about 90% of the sulfate-linked galactose or GlcNAc residues, 75% of fucosyl residues linked β1-3 or β1-4 to GlcNAc, and a small amount of GlcNAc-Gal linkages. Therefore, when sulfo-fucosylated oligosaccharide was treated by methanolysis, the desulfated-defucosylated product appeared as the main peak and various other peaks such as sulfo-defucosylated product and desulfated-fucosylated product appeared. A14 was methanolyzed and the products appeared at the position of Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc (V 3 Fucα-1,2 Lc 6 ), Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc
( 1,2 Lc 6 ), sulfated-nonfucosylated product coinciding with A10-1, and Lc 4 on the map (data not shown). The results of methanolysis suggested that A14 was a sulfated form of Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc. Digestion of A14 with α1,3/4-fucosidase resulted in conversion to A10-1, in agreement with the result of methanolysis (Figure 3) . It has been reported that Jack bean β-galactosidase can hydrolyze Galβ1-4(HSO 3 -6)GlcNAc, whereas β1-4 galactosidase from Streptococcus pneumoniae cannot hydrolyze the linkage. After defucosylation, A14 could be digested with Jack bean β-galactosidase, but not with β1-4 galactosidase from S. pneumoniae, and the position of the agalacto form is identical to A5 on the map (Figure 3) . Digestion of the agalacto form with human placental β-N-acetylhexosaminidase, which is able to cleave terminal HSO 3 -6GlcNAc residues, released a HexNAc-HSO 3 residue, as measured by mass spectrometry (data not shown), and the product of the digest coincided with the position of the reference compound Lc 4 (Figure 3) . These results indicate that the sulfate residue of A14 is linked to the 6-position of a subterminal GlcNAc (Table IV) .
The structures of A20 and A6 were predicted to be Galβ1-4(Fucα1-3)(HSO 3 -6)GlcNAcβ1-3Galβ1-4(Fucα1-3) GlcNAcβ1-3Galβ1-4Glc and Galβ1-4(Fucα1-3)(HSO 3 -6) GlcNAcβ1-3Galβ1-4Glc by combination of methanolysis, enzymatic digestion with α1,3/4-fucosidase, Jack bean β-galactosidase and β1-4 galactosidase from S. pneumoniae, and mass spectrometry analysis, as was performed in the analysis of A14 (Figure 3 ). After digestion with α1,3/4-fucosidase, A20 was converted to A15 (Figure 3) . A13-2, A16-2, A17, A19, and A21 are monosialylated, monosulfated GSLs. Sialic acid is linked α2-3 to the terminal residue of A16-2 and A21 and linked α2-6 to the terminal residue of A13-2 and A19 as determined by the specificity of α2,3-silalidase digestion as described in Material and methods. The digestion products of A13-2, A16-2, A19, and A21 corresponded to A10-1, A14, A15, and A20, respectively, on the map (Figure 3) . Although A17 is also a monosialylated, monosulfated GSL, the sialic acid is not linked to terminal galactose. In contrast to A13-2, A16-2, A19, and A21, A17 could not be digested with α2,3-sialidase even in conditions where this enzyme cleaves both the α2-3 and α2-6 linkages to the terminal residue but could be digested with neuraminidase from Arthrobacter ureafaciens which cleaves sialic acid linked to internal residues as well as sialic acid α2-3 and α2-6 linked to the terminal residue. This result suggests that sialic acid is linked to an internal residue of A17. A17 could be digested with α1,3/4-fucosidase. After α1,3/4-fucosidase and neuraminidase digestion, A17 was converted to A10-1 (Figure 3 ). These results indicate that the structure of A17 is such that sialic acid is attached to an internal residue, probably an internal GlcNAc, of Galβ1-4(Fucα1-3)(HSO 3 -6)GlcNAc-Galβ1-3GlcNAcβ1-3Galβ1-4Glc. To determine the position of sialylation, A17 was sequentially digested with α1,3/4-fucosidase, Jack bean β-galactosidase, and then human placental β-N-acetylhexosaminidase. The digestion product was identical to LST-b, Galβ1-3(NeuAcα2-6)GlcNAcβ1-3Galβ1-4Glc, as expected (Figure 3) .
The structures of A5, A6, A10-1, A13-2, A14, A15, A16-2, A17, A19, A20, and A21 are presented in Table IV .
The structure of disialylated GSLs, A10-2, and A13-1 A10-2 and A13-1 are disialylated on a tetrasaccharide backbone (Table III) . A10-2 was digested with α2,3-sialidase in conditions in which this enzyme specifically cleaves the α2-3 linkage (condition 1). The digestion product corresponded to LST-b, Galβ1-3(NeuAcα2-6)GlcNAcβ1-3Galβ1-4Glc (data not shown). The structure of A10-2 is predicted to be NeuAcα2-3Galβ1-3(NeuAcα2-6)GlcNAcβ1-3Galβ1-4Glc. Similarly, A13-1 was sequentially digested with α2,3-sialidase in condition 1, followed by α1,3/4-fucosidase. The digestion product was identical to LST-b. The structure of A13-1 is therefore predicted to be NeuAcα2-3Galβ1-3(NeuAcα2-6)(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc.
The predicted structures of the acidic and neutral GSLs of CCs from case 1 are presented in Table IV .
Structures of GSLs of colon cancer cells and normal colon epithelial cells from case 2
Although a variety of unusual GSLs were found in the CCs from case1 as shown above, the profiles of GSLs from CCs and NCs from case 2 are very similar to those observed in the other patients reported in the recent paper and subsequent analyses, except that two sulfated GSLs are included in the acidic fraction as minor components. Hence, only the profiles of the acidic GSLs of CCs and NCs from case 2 are shown in Figure 4 . Thirteen peaks (A1-A13) and nine peaks were obtained from the 3 . Sequential digestion and methanolysis of PA-oligosaccharides, A5, A6, A10-1, A13-2, A14, A15, A16-2, A17, A19, A20, and A21. Circles indicate the positions of A5, A6, A10-1, A13-2, A14, A15, A16-2, A17, A19, A20, and A21. Thick-line, thin-line, thick dotted-line, and thin dotted-line arrows indicate the direction of the change after glycosidase digestion or methanolysis of A20, A17, A14, and A6, respectively. The thick broken line indicates the direction of the change after α2-3 sialidase digestions of A16-2 and A21 under conditions where the enzyme specifically digests sialic acid in the α2-3 linkage. The thin broken line indicates the direction of the change after α2-3 sialidase digestions of A13-2 and A19 under conditions where the enzyme digests sialic acid in both α2-3 and α2-6 linkages. The thin broken line from A19 to A15 is curved so as not to cross A17. Glycosidases are shown beside each line. Enzyme abbreviations are: 2,3-S; α2,3-sialidase under conditions where the enzyme specifically digests sialic acid in the α2-3 linkage, 2,6-S; α2,3-sialidase under conditions where the enzyme digests sialic acid in both α2-3 and α2-6 linkages, 1,3/4-F; α1,3/4-fucosidase, G; β-galactosidase from Jack bean, Hex; β-N-acetylhexosaminidase from human placenta, N; α-sialidase (neuraminidase) from Arthrobacter ureafaciens. M indicates methanolysis. X marks the positions of the standard compounds. Closed triangles mark the positions on the way in sequential enzymatic digestion. acidic GSLs of the CCs and NCs, respectively (Figure 4) . Each of these peaks was further purified by reversed-phase HPLC. Peaks A8, A9, and A11 in CCs were separated by reversedphase HPLC into two major components and designated A8-1, A8-2, A9-1, A9-2, A11-1, and A11-2. All nine peaks from NCs were separated by reversed-phase HPLC into single components. Additionally, purified PA-oligosaccharides were subjected to LC/ESI MS/MS. From a comparison of the positions on the map to the positions of standard PA-oligosaccharides, all the peaks, except A11-1 and A12 in CCs, were matched to the reference standard oligosaccharides we had already acquired. Their structures were also confirmed by mass spectrometry analyses. The structures of the acidic GSLs of CCs from case 2 are listed in Table V . Expression of SM3 (A1), GM3 (A2), and GD3 (A3) in CCs and NCs are very similar. Other ganglio series GSLs such as GD1a (A6), GM1 (A14), and GD1b (A15) were decreased or disappeared in malignant transformation. LST-c (A7) was increased, and other neolacto and lacto series GSLs, SLe x (A8-1), IV 2 FucαIV 6 NeuAcα-nLc 4 (A8-2), SLe a (A9-1), VI 3 NeuAcα-nLc 6 (A10), A11-1, VI 6 NeuAcα-nLc 6 (A11-2), A12, and VI 6 NeuAcαIII 3 Fucα-nLc 6 (A13) appeared in carcinogenesis, as minor components. Unmatched oligosaccharides, A11-1 and A12 in CCs, were monosulfated, as evidenced by mass spectrometry analyses, and A12 of case 2 was identical to A20 of case 1 as judged by 2D mapping and mass spectrometry analysis.
The structure of A11-1 was monosulfated, difucosylated, on a hexasaccharide backbone, as evidence by mass spectrometry analysis. The elution position of A11-1 on two types of HPLC (NP 5.87, RP 3.37) corresponded to the newly synthesized monosulfated difucosylated PA-oligosaccharides, HSO 3 -3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glu, (3 -sulfo-V 3 FucαIII 3 Fucα-nLc 6 ), and HSO 3 -3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glu (3 -sulfo-V 4 FucαIII 3 Fucα-2,1 Lc 6 ), but not other isomers (Table II) . Further analysis to determine the structure of A11-1 could not be performed due to the limited amount of A11-1. However, the former structure ending in a 3 -sulfo Le x structure is more probable as described below. Among the GSLs of CCs from case 2 having a hexasaccharide backbone, derivatives of nLc 6 are dominant, and those being of a type-1 and -type-2 hybrid are very minor (data not shown). A further reason concerns the substrate specificity of sulfotransferase. Four kinds of βGal-3-O-sulfotransferases (Gal3STs), Gal3ST-1, Gal3ST-2, Gal3ST-3, and Gal3ST-4, catalyzing the transfer of a sulfate group from the donor substrate PAPS to the C3 position of the nonreducing terminal Gal residue of carbohydrate chains, have been identified (Honke et al. 1997 El-Fasakhany et al. 2001; Seko et al. 2001; Suzuki et al. 2001) . Among them, Gal3ST-2 and Gal3ST-3 are capable of transferring a sulfate residue to the terminal galactose of type-1 or type-2 lactosamine chains. However, type 2 chains serve as good acceptors, whereas type 1 chains serve as poor acceptors for Gal3ST3. In terms of Gal3ST2, Honke et al. (2001) demonstrated using PA-nLc 4 and PA-Lc 4 as model substrates that it acts on both type 1 chains and type 2 chains. Although we also confirmed this substrate specificity of Gal3ST2 using the same type-1 and type-2 tetrasaccharides, we found that when we synthesized the 3 -sulfated standard oligosaccharides using nLc 6 , Lc 6 , and two types of type-1 and type-2 hybrid ( 1,2 Lc 6 and 2,1 Lc 6 ) as acceptors (data not shown), Gal3ST2 much prefers to add sulfate to the terminal galactose ending type 2 chains of hexasaccharides above the terminal galactose ending type 1 chains of hexasaccharides. The predicted structures of the acidic GSLs of CCs from case 2 are presented in Table V .
Discussion
In our recent study, we identified 27 and 28 kinds of acidic and neutral GSLs, respectively, from CCs and NCs of 16 patients and obtained quantitatively and qualitatively precise structures (Misonou et al. 2009 ). Even though extensive structural analyses of CCs and NCs were performed, we found in subsequent structural analyses that CCs from two patients had a number of GSLs, which could not be found in the CCs and NCs from the other patients, while the NCs from the same patients displayed normal GSL structures. The CCs from these two patients are estimated to have low metastatic potential. We demonstrated that the carbohydrate structures of these CCs have a common feature in that both include sulfated oligosaccharides linked at two different positions: the C6 position of GlcNAc and the C3 position of galactose, besides SM3. Furthermore, the structures from the CCs of case 1, but not case 2, include derivatives of 1,2 Lc 6 . SM3 was the only sulfated GSL found in both the CCs and NCs of many of the cases. However, in the CCs from two cases, sulfate is linked to the C6 position of subterminal GlcNAc and to the C3 position of terminal galactose with or without sialylation or fucosylation, to form a variety of sulfated structures. GSLs from case 1 include a variety of GSLs sulfated at 6-O-GlcNAc forming 6-sulfo lactosamine (A10-1, A15), 6-sulfo Le x (A6, A14, A17, A20), 6 -sialyl 6-sulfo lactosamine (A13-2, A19), 3 -sialyl 6-sulfo Le x (A16-2, A21), and one GSL (SM3 apart) sulfated at C3 galactose to form 3 -sulfo lactosamine (A3). Furthermore, two unusual structures, sulfated at terminal GlcNAc (A5) and sulfated at the subterminal fifth GlcNAc with sialylation at an internal third GlcNAc (A17) on a hexasaccharide backbone, were also detected. Generation of sulfated terminal GlcNAc (A5) is thought to be due to failure of the addition of galactose to sulfated GlcNAc residues rather than an artifact of removal of galactose by galactosidase because GSLs terminated at the fifth GlcNAc have not been found in CCs or NCs in our study with the exception of A5. In the CCs from case 2, a single oligosaccharide sulfated at the C6 position of GlcNAc and a single oligosaccharide sulfated at the C3 position of galactose were found, forming 6-sulfo Le x (A12) and 3 -sulfo Le x (A11-1), respectively. To our knowledge, this is the first report of the presence of the various sulfated GSLs including 6-O-sulfation of GlcNAc and 3 -sulfation of terminal galactose (except for SM3), although some of the structures are found in keratan sulfate as well as N-linked and O-linked glycans (Dickenson et al. 1992; Yuen et al. 1992; Hemmerich et al. 1995; Murakami et al. 2007) .
In terms of GSLs having hexasaccharide backbones, oligosaccharides extending type 2 chains or type 1 chains to nLc 4, such as V 3 FucαIII 3 Fucα-nLc 6 , VI 3 NeuAcα-nLc 6, VI 6 NeuAcαIII 3 Fucα-nLc 6 , and V 4 FucαIII 3 Fucα-2,1 Lc 6 , are mostly observed in both CCs and NCs. However, elongation of type 1 or type 2 chains to Lc 4 to form Lc 6 or 1,2 Lc 6 was found in the CCs from case 1. Besides case 1, fucosylated or sialylated derivatives of these structures were also found in CCs from two other patients as described in our previous report (cases 7 and 16) (Misonou et al. 2009 ). Furthermore, the presence of the derivative of Lc 6 , V 4 FucαIII 4 Fucα-Lc 6 , in various human cancer tissues has been reported (Stroud et al. 1991) . Although GSLs having the structure of 1,2 Lc 6 have been isolated from human meconium (Karlsson and Larson 1981) (but not from any other human tissues to date), the presence of these structures in cancer tissues or cells suggests that the structures can be generated in particular types of cells.
In our previous and subsequent analyses, seven patients were classified as stage II according to the TNM classification because the tumor invaded through the muscularis propria without any lymph node metastases and distant organ metastases. Our study showed that the CCs had the sulfated GSLs in two of these cases. The physiological relevance of the sulfated GSLs in CCs is not clear at present. However, given the clinical features of the cases and expression pattern which show that a variety and high levels of sulfated GSLs are expressed in CCs of undoubtedly low metastatic potential (case 1), we propose a hypothesis that they may, at least in part, be involved in the observed low metastatic potential (even though the number of samples is still small). The interaction between sulfated GSLs on the surface of cancer cells and lectins, such as selectins, is worthy of discussion given that sulfated oligosaccharide determinants have been shown to function as ligands of selectins. In particular, the sialyl 6-sulfo
